A statement released earlier today by Vetr Inc. about Merrimack Pharmaceuticals Inc (NASDAQ:MACK) bumps the target price to $10.86
- Updated: November 28, 2016
Having a price of $6.08, Merrimack Pharmaceuticals Inc (NASDAQ:MACK) traded -5.15% lower on the day. With the last close up 7.58% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same period. Merrimack Pharmaceuticals Inc has recorded a 50-day average of $5.61 and a two hundred day average of $5.65. Volume of trade was down over the average, with 0 shares of MACK changing hands under the typical 3,248,440
Stating a potential upside of 0.79%, Vetr Inc. upped the price target of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to $10.86
On 11/28/2016, Vetr Inc. released a statement on Merrimack Pharmaceuticals Inc (NASDAQ:MACK) upped the target price from $0.00 to $5.60 that suggested a downside of -0.13%.
See Chart Below
Merrimack Pharmaceuticals Inc has a 52 week low of $4.39 and a 52 week high of $9.40 The company’s market cap is currently $0.
About Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.